Business Development and Lead Generation for Life Sciences

Running a CRO or CDMO without a dedicated BD person means your pipeline is inconsistent, your prospecting is reactive, and your growth depends on referrals you can't control. Hiring a full-time VP of Business Development solves the problem but costs $150,000 to $200,000 per year before benefits, equity, and onboarding time.

Fractional business development is a third option: senior BD expertise, applied to your specific pipeline challenges, without the full-time cost or commitment.

What Is Fractional Business Development in Life Sciences?

Fractional business development means working with an experienced BD professional on a part-time or project basis. You get the strategy, the outreach, and the market expertise of a senior BD director, at a fraction of the cost of a full-time hire.

This is not the same as hiring a generalist freelancer. A fractional BD consultant for life sciences needs to understand how pharma sponsors evaluate CRO partners, what goes into a credible RFP response, and why a 12-month sales cycle is normal for first-time CDMO engagements. These are not skills a generalist agency can replicate.

It is also not the same as a lead generation agency. Lead generation delivers contact lists. Fractional BD delivers pipeline strategy, relationship development, and market positioning, the work that converts contacts into qualified conversations.

When Does a Small CRO or CDMO Need Fractional BD?

You have no dedicated BD person

Your scientific team is excellent. Your delivery track record is strong. But no one is consistently prospecting, following up, or building the market relationships that lead to new contracts. Business development happens in between everything else, which means it rarely happens.

Your pipeline is inconsistent

You close projects, then spend weeks finding the next one. The feast-and-famine cycle is the most common growth problem for small CROs and CDMOs, and it comes from inconsistent BD effort, not from lack of capabilities.

You want to enter the US or UK market

Breaking into a new geography requires local market knowledge: who the active sponsors are, which conferences matter, how procurement decisions are made in that market. Getting this wrong is expensive. Getting it right with a guide is faster.

You need senior BD expertise without a $150K+ annual commitment

A fractional model lets you access the level of BD expertise your business needs now, scale it up or down as your pipeline evolves, and keep your fixed cost base manageable while you grow.

What Fractional BD with Corstrate Includes

Corstrate works with small CROs, CDMOs, regulatory consultancies, PV companies, data management and medical writing firms, and other life sciences service providers. The scope adapts to what your business actually needs.

BD strategy and ICP definition

Before any outreach, the work starts with clarity: who is your ideal client, what problems do you solve better than anyone else, and what does your competitive position look like in your target geography. A clear ICP makes every subsequent BD activity more efficient.

Prospect research and buying signals analysis

Identifying the right prospect at the right moment is what separates effective BD from cold email volume. Buying signals in the life sciences context include new clinical trial registrations, biotech funding rounds, sponsor hiring patterns, and therapeutic pipeline developments that indicate an upcoming outsourcing need. These signals require scientific literacy to interpret. A general marketing team will miss them.

Outreach and pipeline management

Structured outreach using your existing CRM or our own built tool, with consistent follow-up, documented pipeline stages, and regular reporting. CRMs in use: HubSpot, Salesforce, Pipedrive, Monday.

Conference and event representation

Face-to-face relationships remain the fastest way to build trust in the life sciences services market. CPHI, BIO, DCAT Week, ASCO, ASMO, and other sector events are key touchpoints. Corstrate can represent your company at these events, run pre-event outreach, and follow up on the meetings generated.

Reporting and market feedback

Weekly and monthly pipeline reports and market feedback so you understand what is moving, what is stalled, and what the competitive landscape looks like in your target accounts.

Buying Signals in Life Sciences BD

Buying signals are indicators that a prospect company is about to increase its outsourcing activity. In life sciences, these signals are specific and require sector knowledge to interpret correctly.

For a CRO or CDMO, relevant buying signals include:

A biotech announces a Series B or C funding round focused on clinical development
A pharma sponsor registers a new Phase II or III trial on clinicaltrials.gov
A sponsor hires a VP of Clinical Operations or a Head of CMC, indicating scale-up
A company expands its therapeutic pipeline into a new indication that requires capabilities they do not have in-house
A sponsor's existing CRO or CDMO relationship ends (visible through LinkedIn, regulatory filings, or conference conversations)

Identifying these signals consistently, and reaching out at the right moment with a relevant message, is what produces qualified meetings rather than ignored cold emails.

Buying signals for CROs and CDMOs include new clinical trial registrations, biotech funding rounds, and sponsor hiring patterns that indicate expanding outsourcing needs. Acting on these signals within days of their publication, with a message that demonstrates sector understanding, produces response rates that generic outreach cannot match.

Why Life Sciences BD Requires Sector-Specific Expertise

Selling CRO or CDMO services is not like selling SaaS. Your prospects are clinical operations directors, CMC heads, and procurement teams who evaluate suppliers on regulatory compliance, quality systems, and technical depth. A BD conversation that does not demonstrate familiarity with GCP requirements, RFP processes, and audit readiness signals will not get past the first meeting.

A fractional BD consultant for CROs and CDMOs should understand GCP requirements, RFP processes, and the 6-to-18-month sales cycles typical of the life sciences services market. Without this background, the outreach sounds like it could have been sent to any industry. With it, the message speaks directly to the priorities of the person reading it.

This is the gap that generic marketing agencies and lead generation tools cannot fill.

About Imen Jelassi, Your Fractional BD Partner

Imen Jelassi, PharmD, has spent 14 years in business development for life sciences service providers, including CROs, CDMOs, and regulatory consultancies.

Her background spans both sides of the clinical research process: she started as a Clinical Research Associate, monitoring Phase III and IV trials in various therapeutic areas. She knows what CRO operations look like from the inside, which means she speaks the same technical language as the people she is prospecting.

Since 2012, Imen has worked exclusively in BD for life sciences service companies, covering CROs, CDMOs, regulatory consultancies, PV firms, data management and biostatistics providers, imaging for clinical trials, medical writing companies, and early-stage biotechs.

Her credentials:

PharmD, (2008)
MSc Health Marketing, Négociation et Ventes, Université Pierre et Marie Curie Paris (2015)
HubSpot Certified
GCP and GMP trained
CRMs: HubSpot, Salesforce, Pipedrive, Monday

Her international exposure covers the US, UK, France, Germany, Switzerland, Belgium, the Netherlands, Africa, Asia, and MENA.

Corstrate was founded in 2019 as a BD consultancy dedicated exclusively to small life sciences service providers.

Fractional BD for the US, UK and European Life Sciences Market

United States

The US market is the largest single market for CRO and CDMO services. FDA-regulated environments, a large base of biotech sponsors, and a direct commercial culture make it a priority for service providers looking to scale. Entry requires understanding the FDA regulatory framework, US procurement norms, and which conferences and networks are relevant to your specific service category.

United Kingdom

The UK market has its own regulatory environment post-Brexit, governed by the MHRA alongside ongoing EMA alignment. The CRO and CDMO ecosystem in the UK is dense, with established players and a culture of long-term partnership rather than transactional buying. Market entry here rewards consistency and relationship depth.

Europe

Key European markets for life sciences services include Germany, the Netherlands, Belgium, France, and Switzerland, each with its own cluster of CRO and CDMO activity. Germany and Switzerland have a high concentration of large pharma clients with sophisticated procurement processes. The Netherlands and Belgium are home to several mid-size biotechs actively expanding their pipelines.

Covering multiple geographies simultaneously, rather than sequentially, is an advantage for CROs and CDMOs that want to reduce dependency on a single market.

Frequently Asked Questions

How does fractional BD differ from hiring a full-time BD director?

A full-time BD director is a fixed cost of $150,000 to $200,000+ per year, with benefits, equity, and a ramp-up period before they produce results. A fractional BD consultant brings the same level of expertise with a variable cost structure, no equity dilution, and no recruitment timeline. You pay for the work, not the headcount.

When should a small CRO or CDMO consider outsourcing their business development?

If your pipeline is inconsistent, if you have no dedicated BD person, or if you are trying to enter a new geography without a local network, fractional BD is the fastest way to get structured, expert-led commercial activity in place without a full-time hire.

What types of life sciences service providers benefit from fractional BD?

CROs and CDMOs are the primary target, but the model works for any life sciences service provider selling to pharma, biotech, or medtech sponsors: regulatory consultancies, PV companies, data management and biostats firms, medical writing providers, and early-stage biotechs with a service offering.

How does working with a fractional BD consultant work in practice?

The engagement starts with a strategy session to define your ICP, value proposition, and target geography. From there, Corstrate runs structured outreach on a defined cadence, manages your pipeline, and delivers monthly reporting. The level of involvement is adapted to your needs, from strategic advisory to full BD execution.

What are buying signals and how are they used in life sciences BD?

Buying signals are publicly available indicators that a prospect company is about to increase its outsourcing activity: a new clinical trial registration, a funding round, a senior clinical hire, or a pipeline expansion into a new therapeutic area. Identifying and acting on these signals at the right moment, with a technically credible message, is what produces qualified conversations rather than ignored outreach.

Ready to Build a Consistent BD Pipeline?

If you are running a CRO, CDMO, or life sciences service company and your pipeline is inconsistent, we should talk. Book a free BD consultation to discuss your target markets, your current BD approach, and what a fractional model could look like for your business.

Book a free BD consultation

Not sure yet? See how Corstrate approaches lead generation for life sciences.

Corstrate is a boutique consultancy specializing in fractional and outbound business development for CROs, CDMOs and life sciences service providers.

B2B lead generation for life sciences companies and CRO business development

Who We Help

Our lead generation support is built for companies operating across the life sciences ecosystem, including:

biotech companies
pharma and biopharma service providers
CROs and CDMOs
medtech and diagnostics companies
regulatory, clinical, and scientific consulting firms
life sciences technology providers

We support clients that need a more structured and effective way to generate qualified opportunities, especially when internal business development bandwidth is limited or when growth depends on reaching highly specific decision-makers.

Our Lead Generation Process for Life Sciences Companies

Our approach combines strategic targeting with execution. As a specialized life sciences lead generation agency, we help clients move from broad ambition to structured pipeline generation.

Our process typically includes:

Ideal Client Profile Definition

We define who you should target based on company type, service fit, therapeutic focus, stage of development, geography, and decision-making structure.

Account Mapping and Segmentation

We identify the most relevant organizations and build targeted lists based on your growth priorities. This is especially important for biotech lead generation and life sciences lead generation, where precision matters more than volume.

Messaging Development

We create messaging that reflects your positioning, speaks to your audience’s priorities, and supports stronger engagement across the sales process.

Multi-Channel Outreach

We combine email, LinkedIn, and event-driven follow-up to support multiple channels of engagement and increase the likelihood of meaningful responses.

Lead Qualification

We focus on generating qualified conversations, not vanity metrics. Our goal is to help you connect with decision-makers who are relevant to your offer, timeline, and target market.

CRM Visibility and Ongoing Refinement

We track outreach, monitor what resonates, and refine the approach over time to improve performance and support a more efficient commercial process.

Why Corstrate as Your Life Science Lead Generation Agency

Corstrate is not a generic outbound provider. We are a specialist partner for companies that need lead generation built around the realities of life sciences.

As a life science lead generation agency, we help clients:

generate highly qualified leads
reach highly specialized buyers
strengthen pipeline quality
improve outreach relevance
build a more consistent commercial process

Our work is especially relevant for organizations that need:

build a stronger pipeline in life sciences
reach better-fit biotech and pharma prospects
improve the quality of their outbound outreach
generate more qualified commercial conversations
create a more structured lead generation process

Because we understand the life sciences industry, we can align targeting, messaging, and outreach with the types of purchasing decisions your prospects are actually making.

Lead Generation for Biotech Companies

Biotech lead generation requires a highly targeted approach. Biotech companies often operate with lean teams, evolving pipelines, and specialized priorities. Decision-makers are usually evaluating potential partners based on scientific fit, operational relevance, and timing.

A strong biotech lead generation agency should understand how to build outreach around:

development stage
therapeutic focus
modality
internal team structure
funding context
strategic milestones

This is why biotech b2b lead generation cannot rely on generic market lists or broad sales language. Effective outreach must be focused and credible.

Lead Generation in Pharma and Biopharma

Lead generation in pharma requires a different rhythm and level of rigor than many other industries. In pharma and biopharma environments, commercial conversations often involve multiple stakeholders, formal purchasing decisions, and internal evaluation across several functions.

A structured lead generation pharma approach should support:

clear value positioning
relevance to specific business needs
visibility across multiple channels
strong follow-up discipline
consistent quality in outreach

For service providers selling into pharma, relevance is one of the biggest differentiators. The goal is not simply to reach more contacts, but to generate better qualified leads and create opportunities that have real commercial potential.

What Good Lead Generation Looks Like in Life Sciences

The most effective life sciences lead generation programs are built around quality, not volume.

That means:

targeting relevant companies instead of broad databases
engaging decision-makers with clear and useful messaging
supporting outreach with insight and timing
improving the sales process through structured follow-up
focusing on generate qualified outcomes rather than activity alone

This is where many companies benefit from working with a specialized partner rather than a generalist agency. In the life sciences industry, good outreach is not only about getting replies. It is about starting the right conversations.

Build a Stronger Lead Generation Engine With Corstrate

If you are looking for a more strategic way to generate qualified opportunities, Corstrate can help.

We support life sciences companies with:

targeted account selection
lead generation strategy
messaging development
outbound execution
pipeline support

Whether your goal is to improve biotech lead generation, strengthen life science lead generation services, or build a more scalable life sciences lead generation process, we help turn commercial intent into qualified conversations.

Contact Corstrate to build a more focused and effective lead generation strategy for your company.

Lead Generation FAQ for Life Sciences Companies

What is life science B2B lead generation?

Life science B2B lead generation is the process of identifying, targeting, and engaging relevant buyers or partners in biotech, pharma, medtech, CRO, CDMO, and related sectors. It requires more precision than generic B2B outreach because the market is more technical and decision-making is more specialized.

What makes biotech lead generation different?

Biotech lead generation requires a stronger understanding of scientific context, development stage, internal team structure, and commercial timing. Outreach must be highly relevant and aligned with the realities of biotech organizations.

What makes a good life science lead generation agency?

A good life science lead generation agency combines market understanding, precise targeting, strong messaging, and disciplined execution. It should help you generate qualified leads, not just more contacts.

Can outsourced lead generation work for pharma-facing companies?

Yes. Outsourced support can work well for companies selling into pharma when the approach is specialized, strategic, and aligned with the industry’s buying process. This is especially useful for service providers that need stronger commercial structure without building a full internal team immediately.

What is pharmaceutical lead generation?

Pharmaceutical lead generation is the process of identifying and engaging qualified prospects, such as biotech companies, pharma sponsors, and CROs, to create new business opportunities. Effective pharma lead generation combines targeted outreach, strong positioning, and data-driven strategies to reach decision-makers in clinical development, R&D, and procurement.
A successful pharmaceutical lead generation strategy focuses on niche targeting, high-quality content, and consistent follow-up to convert interest into meetings and revenue. Optimizing content with relevant keywords and clear value propositions is essential to improve visibility and attract qualified leads.

How does biotech lead generation differ from pharma lead generation?

Biotech lead generation differs from pharma lead generation in that it targets earlier-stage companies, often with highly specialized scientific needs and smaller teams. Unlike large pharmaceutical organizations, biotech companies require more tailored messaging and educational content to support decision-making.
A strong biotech lead generation strategy focuses on precision targeting, scientific credibility, and personalized outreach to engage founders, scientists, and clinical leaders. SEO plays a key role by ensuring content is relevant, accurate, and aligned with niche search intent, helping biotech companies reach the right audience effectively

What is fractional business development in the life sciences industry?

Fractional business development in the life sciences industry is a model where biotech, pharmaceutical, CRO, and CDMO companies work with experienced business development professionals on a part-time or flexible basis instead of hiring a full-time team.

This approach gives access to senior-level expertise to define strategy, generate qualified leads, manage outreach, and support deal closing, without the cost and long-term commitment of a full-time hire.

In life sciences, where sales cycles are long and highly specialized, fractional business development helps companies connect scientific capabilities with commercial opportunities, build a predictable pipeline, and accelerate growth.

It is particularly valuable for early-stage biotech companies, small and mid-sized CROs, and organizations expanding into new markets that need experienced support but not a full internal team.